345.00p-5.00 (-1.45%)28 Mar 2024, 16:18
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Maxcyte INC Fundamentals

Company NameMaxcyte INCLast Updated2024-03-28
IndustryMedical DevicesSectorHealthcare
Shares in Issue104.129 mMarket Cap£354.04 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.37EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0699Debt Equity Ratio0.0774
Asset Equity Ratio1.1555Cash Equity Ratio0.7249
Quick Ratio9.7489Current Ratio10.65
Price To Book Value1.9539ROCE0

Maxcyte INC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Maxcyte INC Company Financials

Assets202320222021
Tangible Assets$34.75 m$33.58 m$13.37 m
Intangible Assets000
Investments000
Total Fixed Assets$78.08 m$34.39 m$13.69 m
Stocks$12.23 m$8.58 m$5.20 m
Debtors000
Cash & Equivalents$168.29 m$227.34 m$255.04 m
Other Assets000
Total Assets$268.27 m$286.65 m$284.12 m
Liabilities202320222021
Creditors within 1 year$17.86 m$15.43 m$15.62 m
Creditors after 1 year$18.25 m$17.26 m$5.61 m
Other Liabilities000
Total Liabilities$36.11 m$32.69 m$21.22 m
Net assets$232.17 m$253.97 m$262.90 m
Equity202320222021
Called up share capital$1.04 m$1.02 m$1.01 m
Share Premium$406.93 m$390.82 m$376.19 m
Profit / Loss-$37.92 m-$23.57 m-$19.08 m
Other Equity$232.17 m$253.97 m$262.90 m
Preference & Minorities000
Total Capital Employed$232.17 m$253.97 m$262.90 m
Ratios202320222021
Debt Ratio$0.07$0.06$0.02
Debt-to-Equity$0.08$0.06$0.02
Assets / Equity1.15551.15551.1555
Cash / Equity0.72490.72490.7249
EPS-$0.37-$0.23-$0.21
Cash Flow202320222021
Cash from operating activities-$21.69 m-$14.78 m-$10.68 m
Cashflow before financing-$19.54 m-$11.89 m$224.04 m
Increase in Cash$35.44 m-$36.72 m$29.03 m
Income202320222021
Turnover$41.29 m$44.26 m$33.89 m
Cost of sales$4.74 m$5.10 m$3.65 m
Gross Profit$36.55 m$39.16 m$30.25 m
Operating Profit-$48.30 m-$27.36 m-$18.19 m
Pre-Tax profit-$37.92 m-$23.57 m-$19.08 m

Maxcyte INC Company Background

SectorHealthcare
ActivitiesMaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Latest Interim Date9 Aug 2023
Latest Fiscal Year End Date12 Mar 2024

Maxcyte INC Directors

AppointedNamePosition
2024-03-19Mr. Douglas J SwirskyCHIEF FINANCIAL OFFICER
2023-06-23Mr. Patrick J Balthrop SrDirector
2024-02-29Mr. John Joseph JohnstonNon-Executive Director
2023-12-28Mr. Douglas Arthur DoerflerExecutive Director,President and Chief Executive Officer
2022-03-29Ms. Amanda L. MurphyChief Financial Officer
2024-03-19Mr. Thomas M. RossEVP, GLOBAL SALES & MARKETING
2024-03-20Mr. Maher MasoudExecutive Director,President and Chief Executive Officer
2023-03-21Mr. Cenk SumenChief Scientific Officer
2024-03-19Mr. David I. SandovalGENERAL COUNSEL

Maxcyte INC Contact Details

Company NameMaxCyte Inc
Address22 Firstfield Road, Suite 110, Gaithersburg, 20878
Telephone+1 301 944-1700
Websitehttps://www.maxcyte.com

Maxcyte INC Advisors

RegistrarCapita Asset Services
Phone+44 1534847000
Fax+44 1534847001
AuditorAronson LLC
Phone+1 301 231-6200
Fax+1 301 231-7630
SolicitorCooley LLP
Phone+1 703 456-8000
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorFeldhaus Law Group, P.C.
SolicitorTravers Smith LLP
Phone+44 2072953000
Fax+44 2072953500
SolicitorNorton Rose Fulbright US LLP
Nominated AdviserPanmure Gordon (UK) Ltd
Phone+44 2078862500
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500